BioSpace News Archive

POINT Biopharma Global Inc. today announced financial results for the third quarter ended September 30, 2022, and provided an update on business highlights, including the announcement of a strategic collaboration and exclusive license agreements with Lantheus Holdings Inc.

Zynerba Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2022, and provided an overview of recent operational highlights and a pipeline update.

Mindset Pharma Inc. today announced data from preclinical studies comparing its novel prodrug of psilocin, MSP-1014.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced interim clinical data from cohort 1 of the Phase 1/2 clinical trial of intravitreal 4D-150 for wet AMD.

Urovant Sciences ® Announces Partnership with Thinx Inc. to Help Americans with Overactive Bladder This Travel Season.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended September 30, 2022 and provided a corporate update.

Ascendis Pharma A/S announced it has submitted a Marketing Authorisation Application to the European Medicines Agency for TransCon PTH in adult patients with hypoparathyroidism.

Apexigen, Inc. today announced topline data from an ongoing Phase 2 investigator sponsored trial in collaboration with Columbia University, evaluating sotigalimab, Apexigen’s agonist antibody targeting CD40, in combination with standard of care doxorubicin (dox), in patients with advanced soft tissue sarcoma (STS).

Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced financial results for the third quarter ended September 30, 2022.

Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced financial results for the third quarter ending September 30, 2022 and provided corporate updates.